BLAINJECTIONINJECTABLE
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AVZIVI (bevacizumab) by Bio-Thera Solutions is 12. First approved in 2023.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVZIVI is a monoclonal antibody (bevacizumab) that binds VEGF and blocks its interaction with endothelial cell receptors, preventing new blood vessel formation that fuels tumor growth. It is a biosimilar to reference bevacizumab used across multiple solid tumor indications. The drug leverages anti-angiogenic mechanism to inhibit metastatic disease progression and microvascular growth.
Growth
Recent BLA approval (Dec 2023) as a biosimilar entry positions AVZIVI in a growth phase within an established bevacizumab-dominated market; commercial teams will focus on rapid uptake and payer penetration against reference and competing biosimilars.
Mechanism of Action
12.1 Mechanism of Action Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of…
Worked on AVZIVI at Bio-Thera Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.